ALEC
Alector, Inc. [ALEC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALEC Stock Summary
Top 10 Correlated ETFs
ALEC
Top 10 Correlated Stocks
ALEC
In the News
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ALEC Financial details
ALEC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.34 | 0.27 | 2.58 | 1.62 | 1.16 | |
| Net income per share | -1.62 | -2.35 | -0.35 | -1.62 | -1.56 | |
| Operating cash flow per share | -1.61 | -2.14 | 3.71 | -0.25 | -2.2 | |
| Free cash flow per share | -1.86 | -2.21 | 3.67 | -0.3 | -2.23 | |
| Cash per share | 5.72 | 5.32 | 9.14 | 8.64 | 6.55 | |
| Book value per share | 3.15 | 3.44 | 3.74 | 2.6 | 1.6 | |
| Tangible book value per share | 3.15 | 3.44 | 3.74 | 2.6 | 1.6 | |
| Share holders equity per share | 3.15 | 3.44 | 3.74 | 2.6 | 1.6 | |
| Interest debt per share | 0.78 | 0.66 | 0.59 | 0.33 | 0.46 | |
| Market cap | 1.06B | 1.18B | 1.66B | 761.18M | 668.2M | |
| Enterprise value | 1.02B | 1.18B | 1.38B | 650.18M | 632.56M | |
| P/E ratio | -10.66 | -6.43 | -59.28 | -5.71 | -5.12 | |
| Price to sales ratio | 50.13 | 55.76 | 8.02 | 5.7 | 6.88 | |
| POCF ratio | -10.71 | -7.06 | 5.56 | -37.44 | -3.63 | |
| PFCF ratio | -9.28 | -6.85 | 5.62 | -31.14 | -3.58 | |
| P/B Ratio | 5.46 | 4.4 | 5.52 | 3.55 | 4.98 | |
| PTB ratio | 5.46 | 4.4 | 5.52 | 3.55 | 4.98 | |
| EV to sales | 48.17 | 55.82 | 6.66 | 4.87 | 6.52 | |
| Enterprise value over EBITDA | -8.93 | -6.03 | -36.91 | -4.72 | -4.43 | |
| EV to operating cash flow | -10.29 | -7.06 | 4.62 | -31.98 | -3.43 | |
| EV to free cash flow | -8.92 | -6.86 | 4.67 | -26.6 | -3.39 | |
| Earnings yield | -0.09 | -0.16 | -0.02 | -0.18 | -0.2 | |
| Free cash flow yield | -0.11 | -0.15 | 0.18 | -0.03 | -0.28 | |
| Debt to equity | 0.25 | 0.19 | 0.16 | 0.2 | 0.29 | |
| Debt to assets | 0.11 | 0.1 | 0.06 | 0.06 | 0.06 | |
| Net debt to EBITDA | 0.36 | -0.01 | 7.54 | 0.81 | 0.25 | |
| Current ratio | 11.24 | 9.54 | 15.55 | 15.94 | 3.18 | |
| Interest coverage | 0 | 0 | 0 | 8.48 | 0 | |
| Income quality | 0.94 | 0.88 | -8.22 | 0.15 | 1.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.65 | 2.82 | 0.27 | 0.46 | 0.58 | |
| Research and developement to revenue | 4.74 | 7.44 | 0.91 | 1.57 | 1.98 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.15 | 0.03 | -0.01 | 0.2 | 0.01 | |
| Capex to revenue | -0.72 | -0.24 | -0.02 | -0.03 | -0.02 | |
| Capex to depreciation | -2.74 | -0.69 | -0.39 | -0.49 | -0.27 | |
| Stock based compensation to revenue | 0.77 | 1.45 | 0.2 | 0.35 | 0.44 | |
| Graham number | 10.71 | 13.5 | 5.41 | 9.73 | 7.49 | |
| ROIC | -0.37 | -0.51 | -0.07 | -0.47 | -0.75 | |
| Return on tangible assets | -0.24 | -0.37 | -0.03 | -0.17 | -0.21 | |
| Graham Net | 2.04 | 2.48 | 2.82 | 1.72 | 0.73 | |
| Working capital | 325.63M | 377.31M | 701.5M | 680.86M | 387.86M | |
| Tangible asset value | 194.74M | 267.53M | 300.72M | 214.44M | 134.16M | |
| Net current asset value | 130.27M | 200.79M | 235.78M | 153.23M | 78.14M | |
| Invested capital | 0.25 | 0.19 | 0.16 | 0.2 | 0.29 | |
| Average receivables | 0 | 0 | 3.7M | 4.99M | 1.29M | |
| Average payables | 202K | 1.64M | 3.88M | 4.47M | 3.98M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 13.03 | 7.07 | 0 | |
| Days payables outstanding | 1.01 | 6.99 | 9.15 | 180.48 | 155.73 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 28.02 | 51.65 | 0 | |
| Payables turnover | 361.61 | 52.22 | 39.88 | 2.02 | 2.34 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.51 | -0.68 | -0.09 | -0.62 | -0.97 | |
| Capex per share | -0.25 | -0.06 | -0.04 | -0.05 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.17 | 0.2 | 0.67 | 0.11 | 0.18 | |
| Net income per share | -0.63 | -0.55 | 0.02 | -0.53 | -0.49 | |
| Operating cash flow per share | -0.59 | -0.58 | -0.52 | -0.55 | -0.55 | |
| Free cash flow per share | -0.6 | -0.6 | -0.53 | -0.55 | -0.55 | |
| Cash per share | 8.61 | 8.05 | 7.55 | 7.02 | 6.5 | |
| Book value per share | 2.59 | 2.2 | 2.35 | 1.94 | 1.59 | |
| Tangible book value per share | 2.59 | 2.2 | 2.35 | 1.94 | 1.59 | |
| Share holders equity per share | 2.59 | 2.2 | 2.35 | 1.94 | 1.59 | |
| Interest debt per share | 0.45 | 0.45 | 0.49 | 0.48 | 0.52 | |
| Market cap | 763.91M | 514.4M | 501.82M | 543.85M | 673.39M | |
| Enterprise value | 652.91M | 361.03M | 411.22M | 482.12M | 637.75M | |
| P/E ratio | -3.64 | -2.8 | 91.24 | -3.06 | -4.06 | |
| Price to sales ratio | 52.9 | 31.08 | 8.93 | 59.71 | 44.33 | |
| POCF ratio | -15.61 | -10.6 | -11.67 | -11.69 | -14.62 | |
| PFCF ratio | -15.37 | -10.38 | -11.35 | -11.71 | -14.54 | |
| P/B Ratio | 3.56 | 2.81 | 2.56 | 3.35 | 5.02 | |
| PTB ratio | 3.56 | 2.81 | 2.56 | 3.35 | 5.02 | |
| EV to sales | 45.22 | 21.82 | 7.32 | 52.93 | 41.98 | |
| Enterprise value over EBITDA | -11.78 | -7.52 | -302.81 | -9.98 | -14.11 | |
| EV to operating cash flow | -13.35 | -7.44 | -9.56 | -10.36 | -13.84 | |
| EV to free cash flow | -13.14 | -7.28 | -9.3 | -10.38 | -13.77 | |
| Earnings yield | -0.07 | -0.09 | 0 | -0.08 | -0.06 | |
| Free cash flow yield | -0.07 | -0.1 | -0.09 | -0.09 | -0.07 | |
| Debt to equity | 0.2 | 0.23 | 0.21 | 0.25 | 0.29 | |
| Debt to assets | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Net debt to EBITDA | 2 | 3.19 | 66.71 | 1.28 | 0.79 | |
| Current ratio | 15.94 | 6.91 | 4.9 | 3.95 | 3.18 | |
| Interest coverage | 9.49 | 9.71 | 0 | 0 | -9.2 | |
| Income quality | 0.93 | 1.06 | -31.28 | 1.05 | 1.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.02 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.07 | 0.89 | 0.24 | 1.47 | 0.98 | |
| Research and developement to revenue | 3.77 | 3.14 | 0.82 | 5.09 | 3.14 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.02 | 0.03 | 0 | 0.01 | |
| Capex to revenue | -0.05 | -0.06 | -0.02 | 0.01 | -0.02 | |
| Capex to depreciation | -0.36 | -0.49 | -0.55 | 0.04 | -0.1 | |
| Stock based compensation to revenue | 0.76 | 0.66 | 0.18 | 1.1 | 0.76 | |
| Graham number | 6.08 | 5.23 | 0.93 | 4.81 | 4.19 | |
| ROIC | -0.19 | -0.19 | -0.01 | -0.21 | -0.23 | |
| Return on tangible assets | -0.07 | -0.06 | 0 | -0.07 | -0.07 | |
| Graham Net | 1.71 | 1.29 | 1.48 | 1.04 | 0.73 | |
| Working capital | 680.86M | 586.7M | 515.72M | 457.75M | 387.86M | |
| Tangible asset value | 214.44M | 183.02M | 196.31M | 162.56M | 134.16M | |
| Net current asset value | 153.23M | 120.68M | 135.56M | 103.31M | 78.14M | |
| Invested capital | 0.2 | 0.23 | 0.21 | 0.25 | 0.29 | |
| Average receivables | 4.54M | 3.64M | 6.26M | 9.15M | 5.23M | |
| Average payables | 4.37M | 3.66M | 3.9M | 4.67M | 4.23M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 16.12 | 25.56 | 12.53 | 103.4 | 0 | |
| Days payables outstanding | 178.42 | 133.84 | 188.27 | 186.58 | 51.56 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 5.58 | 3.52 | 7.18 | 0.87 | 0 | |
| Payables turnover | 0.5 | 0.67 | 0.48 | 0.48 | 1.75 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.24 | -0.25 | 0.01 | -0.27 | -0.31 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
ALEC Frequently Asked Questions
What is Alector, Inc. stock symbol ?
Alector, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol ALEC
What is Alector, Inc. stock quote today ?
Alector, Inc. stock price is $5.64 today.
Is Alector, Inc. stock public?
Yes, Alector, Inc. is a publicly traded company.
Company Profile
- Volume Average 726.79K
- Market Capitalization 576.41M
- Employee 244
- CEO Dr. Arnon Rosenthal Ph.D.
- Headquarters South San Francisco,CA,US
- IPO Date 2019-02-07
-
Website
https://www.alector.com 
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
